Literature DB >> 16978070

Etanercept reduces late endotoxin-induced pulmonary hypertension in the pig.

D Mutschler1, G Wikström, L Lind, A Larsson, A Lagrange, M Eriksson.   

Abstract

To evaluate whether etanercept, a tumor necrosis factor (TNF)-blocking agent, may counteract hemodynamic deterioration in endotoxemic shock, we designed a prospective, randomized placebo-controlled trial with parallel groups, consisting of 13 pigs aged 10-14 weeks receiving general anesthesia. Five pigs were given 25 mg of etanercept, 1 h before the start of a 4-h continuous infusion of endotoxin. Another 5 pigs were given the corresponding volume of saline, 1 h before the start of a 4-h continuous infusion of endotoxin. Three pigs were given 25 mg of etanercept, 1 hr before the start of a 4-h continuous infusion of saline. At 1 h of endotoxemia, mean pulmonary arterial pressure (MPAP) and pulmonary vascular resistance index (PVRI) increased identically in both groups of pigs receiving endotoxin. Thereafter, two distinct different patterns in hemodynamics were observed. TNF-blocked pigs showed significantly lower MPAP and PVRI compared to controls. In the etanercept-treated endotoxemic pigs, Doppler analysis of the diastolic mitral inflow demonstrated a significantly increased E/A-ratio (early mitral wave inflow was divided by the atrial wave) at 2 h. The TNFblocking agent etanercept normalized two hemodynamic features of endotoxin-induced septic shock in pigs: (1) the sustained pulmonary hypertension and (2) diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978070     DOI: 10.1089/jir.2006.26.661

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  11 in total

Review 1.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

2.  Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs.

Authors:  Kalina Atanasova; Steven Van Gucht; Kristien Van Reeth
Journal:  Vet Immunol Immunopathol       Date:  2010-04-13       Impact factor: 2.046

3.  TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.

Authors:  Liam A Hurst; Benjamin J Dunmore; Lu Long; Alexi Crosby; Rafia Al-Lamki; John Deighton; Mark Southwood; Xudong Yang; Marko Z Nikolic; Blanca Herrera; Gareth J Inman; John R Bradley; Amer A Rana; Paul D Upton; Nicholas W Morrell
Journal:  Nat Commun       Date:  2017-01-13       Impact factor: 14.919

Review 4.  Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.

Authors:  Kurt W Prins; Thenappan Thenappan; E Kenneth Weir; Rajat Kalra; Marc Pritzker; Stephen L Archer
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

Review 5.  Novel Advances in Modifying BMPR2 Signaling in PAH.

Authors:  Svenja Dannewitz Prosseda; Md Khadem Ali; Edda Spiekerkoetter
Journal:  Genes (Basel)       Date:  2020-12-23       Impact factor: 4.096

Review 6.  Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Authors:  Benjamin J Dunmore; Rowena J Jones; Mark R Toshner; Paul D Upton; Nicholas W Morrell
Journal:  Cardiovasc Res       Date:  2021-09-28       Impact factor: 10.787

7.  Single intraperitoneal injection of monocrotaline as a novel large animal model of chronic pulmonary hypertension in Tibet minipigs.

Authors:  Guang-qiao Zeng; Rong Liu; Hai-xing Liao; Xin-feng Zhang; Yuan-xin Qian; Bao-hua Liu; Qing-hong Wu; Jin Zhao; Wei-wang Gu; Hong-tao Li
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

Review 8.  Inflammatory cytokines in pulmonary hypertension.

Authors:  Alexandra Groth; Bart Vrugt; Matthias Brock; Rudolf Speich; Silvia Ulrich; Lars C Huber
Journal:  Respir Res       Date:  2014-04-16

Review 9.  Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective.

Authors:  Thomas Koudstaal; Karin A Boomars; Mirjam Kool
Journal:  J Clin Med       Date:  2020-02-19       Impact factor: 4.241

Review 10.  Senescence Alterations in Pulmonary Hypertension.

Authors:  Inés Roger; Javier Milara; Nada Belhadj; Julio Cortijo
Journal:  Cells       Date:  2021-12-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.